![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GPR12 |
Gene summary for GPR12 |
![]() |
Gene information | Species | Human | Gene symbol | GPR12 | Gene ID | 2835 |
Gene name | G protein-coupled receptor 12 | |
Gene Alias | GPCR12 | |
Cytomap | 13q12.13 | |
Gene Type | protein-coding | GO ID | GO:0006873 | UniProtAcc | A8K2F5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2835 | GPR12 | HCC1 | Human | Liver | HCC | 3.07e-08 | 1.08e+00 | 0.5336 |
2835 | GPR12 | HCC2 | Human | Liver | HCC | 6.20e-11 | 9.44e-01 | 0.5341 |
2835 | GPR12 | HCC5 | Human | Liver | HCC | 4.10e-14 | 6.60e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GPR12 | SNV | Missense_Mutation | novel | c.557C>T | p.Ser186Phe | p.S186F | P47775 | protein_coding | deleterious(0.01) | possibly_damaging(0.689) | TCGA-A2-A25B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | PD |
GPR12 | SNV | Missense_Mutation | c.352N>A | p.Gly118Ser | p.G118S | P47775 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
GPR12 | SNV | Missense_Mutation | rs752179748 | c.962C>T | p.Pro321Leu | p.P321L | P47775 | protein_coding | deleterious(0.04) | benign(0.407) | TCGA-D8-A13Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
GPR12 | SNV | Missense_Mutation | c.454A>T | p.Arg152Trp | p.R152W | P47775 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
GPR12 | SNV | Missense_Mutation | rs184863730 | c.553G>A | p.Glu185Lys | p.E185K | P47775 | protein_coding | tolerated(0.83) | benign(0.227) | TCGA-PN-A8MA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
GPR12 | SNV | Missense_Mutation | novel | c.794N>C | p.Met265Thr | p.M265T | P47775 | protein_coding | tolerated(0.32) | benign(0.065) | TCGA-VS-A8QM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
GPR12 | SNV | Missense_Mutation | c.352N>A | p.Gly118Ser | p.G118S | P47775 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
GPR12 | SNV | Missense_Mutation | rs753635977 | c.985N>T | p.Arg329Cys | p.R329C | P47775 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AA-3680-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | PD |
GPR12 | SNV | Missense_Mutation | c.566G>A | p.Ser189Asn | p.S189N | P47775 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
GPR12 | SNV | Missense_Mutation | c.353N>A | p.Gly118Asp | p.G118D | P47775 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2835 | GPR12 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | NEOCYCLOCITRINOL B | NEOCYCLOCITRINOL B | 18656987 | |
2835 | GPR12 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | CYCLOCITRINOL | CYCLOCITRINOL | 18656987 | |
2835 | GPR12 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | 24-EPI-CYCLOCITRINOL | CHEMBL496266 | 18656987 | |
2835 | GPR12 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135651564 | ||
2835 | GPR12 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | agonist | 135651563 | ||
2835 | GPR12 | DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR | NEOCYCLOCITRINOL C | NEOCYCLOCITRINOL C | 18656987 |
Page: 1 |